Maira Caleffi

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/6938639/publications.pdf Version: 2024-02-01



MAIDA CALEEEL

#	Article	IF	CITATIONS
1	Challenge of Incorporating New Drugs for Breast Cancer in Brazil: A Proposed Framework for Improving Access to Innovative Therapies. JCO Global Oncology, 2021, 7, 474-485.	0.8	2
2	Recommendations for Advancing the Diagnosis and Management of Hereditary Breast and Ovarian Cancer in Brazil. JCO Global Oncology, 2020, 6, 439-452.	0.8	25
3	Navegação de enfermagem na atenção ao câncer de mama durante a pandemia: relato de experiência / Nursing navigation in breast cancer care during the pandemic: an experience report. Journal of Nursing and Health, 2020, 10, .	0.2	2
4	Body image (dis)satisfaction among low-income adult women. Clinical Nutrition, 2019, 38, 1317-1323.	2.3	21
5	Performance of the Gail and Tyrer-Cuzick breast cancer risk assessment models in women screened in a primary care setting with the FHS-7 questionnaire. Genetics and Molecular Biology, 2019, 42, 232-237.	0.6	12
6	Assessment of potential risk factors for breast cancer in a population in Southern Brazil. Breast Cancer Research and Treatment, 2018, 169, 125-131.	1.1	7
7	Body Weight and Breast Cancer: Nested Case–Control Study in Southern Brazil. Clinical Breast Cancer, 2018, 18, e797-e803.	1.1	7
8	p53 signaling pathway polymorphisms, cancer risk and tumor phenotype in TP53 R337H mutation carriers. Familial Cancer, 2018, 17, 269-274.	0.9	11
9	Estimation of Premature Deaths From Lack of Access to Anti-HER2 Therapy for Advanced Breast Cancer in the Brazilian Public Health System. Journal of Global Oncology, 2017, 3, 201-207.	0.5	20
10	Screening for germline BRCA1, BRCA2, TP53 and CHEK2 mutations in families at-risk for hereditary breast cancer identified in a population-based study from Southern Brazil. Genetics and Molecular Biology, 2016, 39, 210-222.	0.6	21
11	Rare germline variant (rs78378222) in the TP53 3' UTR: Evidence for a new mechanism of cancer predisposition in Li-Fraumeni syndrome. Cancer Genetics, 2016, 209, 97-106.	0.2	19
12	A Neoadjuvant, Randomized, Open-Label Phase II Trial of Afatinib Versus Trastuzumab Versus Lapatinib in Patients With Locally Advanced HER2-Positive Breast Cancer. Clinical Breast Cancer, 2015, 15, 101-109.	1.1	40
13	A DNA repair variant in POLQ (c1060A > G) is associated to hereditary breast cancer patients: a case–control study. BMC Cancer, 2014, 14, 850.	1.1	12
14	Apolipoprotein E genetic polymorphism, serum lipoprotein levels and breast cancer risk: A case-control study. Molecular and Clinical Oncology, 2014, 2, 1009-1015.	0.4	16
15	Prevalence of the TP53 p.R337H Mutation in Breast Cancer Patients in Brazil. PLoS ONE, 2014, 9, e99893.	1.1	49
16	Association of adipokines and adhesion molecules with indicators of obesity in women undergoing mammography screening. Nutrition and Metabolism, 2012, 9, 97.	1.3	14
17	Prevalence of the BRCA1 founder mutation c.5266dupin Brazilian individuals at-risk for the hereditary breast and ovarian cancer syndrome. Hereditary Cancer in Clinical Practice, 2011, 9, 12.	0.6	34
18	The role of breast cancer civil society in different resource settings. Breast, 2011, 20, S81-S87.	0.9	25

MAIRA CALEFFI

#	Article	IF	CITATIONS
19	Breast cancer management in middle-resource countries (MRCs): Consensus statement from the Breast Health Global Initiative. Breast, 2011, 20, S12-S19.	0.9	46
20	Adherence to a Breast Cancer Screening Program and Its Predictors in Underserved Women in Southern Brazil. Cancer Epidemiology Biomarkers and Prevention, 2010, 19, 2673-2679.	1.1	24
21	Population prevalence of hereditary breast cancer phenotypes and implementation of a genetic cancer risk assessment program in southern Brazil. Genetics and Molecular Biology, 2009, 32, 447-455.	0.6	17
22	Development and validation of a simple questionnaire for the identification of hereditary breast cancer in primary care. BMC Cancer, 2009, 9, 283.	1.1	61
23	A model to optimize public health care and downstage breast cancer in limited-resource populations in southern Brazil. (Porto Alegre Breast Health Intervention Cohort). BMC Public Health, 2009, 9, 83.	1.2	20
24	Consistency of self-reported first-degree family history of cancer in a population-based study. Familial Cancer, 2009, 8, 195-202.	0.9	19
25	Detection of R337H, a germline TP53 mutation predisposing to multiple cancers, in asymptomatic women participating in a breast cancer screening program in Southern Brazil. Cancer Letters, 2008, 261, 21-25.	3.2	94
26	Clinical Characterization and Risk Profile of Individuals Seeking Genetic Counseling for Hereditary Breast Cancer in Brazil. Journal of Genetic Counseling, 2007, 16, 363-371.	0.9	22
27	Breast Cancer in Limited-Resource Countries: Early Detection and Access to Care. Breast Journal, 2006, 12, S16-S26.	0.4	145
28	Reducing the Global Breast Cancer Burden: The Importance of Patterns of Care Research. Clinical Breast Cancer, 2005, 6, 412-420.	1.1	19
29	Evidence for an Association of Human Papillomavirus and Breast Carcinomas. Breast Cancer Research and Treatment, 2004, 84, 131-137.	1.1	139
30	Breast Reconstruction with Sensitive TRAM Flap Reinnervation. Breast Journal, 1997, 3, 345-349.	0.4	10
31	P53 gene mutations and steroid receptor status in breast cancer. Clinicopathologic correlations and prognostic assessment. Cancer, 1994, 73, 2147-2156.	2.0	98
32	Factors at presentation influencing the prognosis in breast cancer. European Journal of Cancer & Clinical Oncology, 1989, 25, 51-56.	0.9	14